血管内皮増殖因子B治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0698
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥742,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,113,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Vascular Endothelial Growth Factor B – Pipeline Review, H1 2020
Summary

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 15 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3, 5 and 2 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Age Related Macular Degeneration, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinopathy, Retinopathy Of Prematurity and Uveal Melanoma.

The latest report Vascular Endothelial Growth Factor B – Pipeline Review, H1 2020, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Overview
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Companies Involved in Therapeutics Development
Alteogen Inc
Benitec Biopharma Ltd
Cinnagen Co
Coherus BioSciences Inc
CSL Ltd
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Shandong Boan Biological Technology Co Ltd
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Drug Profiles
aflibercept – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-346 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Dormant Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Discontinued Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Product Development Milestones
Featured News & Press Releases
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Alteogen Inc, H1 2020
Pipeline by Benitec Biopharma Ltd, H1 2020
Pipeline by Cinnagen Co, H1 2020
Pipeline by Coherus BioSciences Inc, H1 2020
Pipeline by CSL Ltd, H1 2020
Pipeline by Formycon AG, H1 2020
Pipeline by Gene Techno Science Co Ltd, H1 2020
Pipeline by Huons Global Co Ltd, H1 2020
Pipeline by Luye Pharma Group Ltd, H1 2020
Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Pipeline by PharmAbcine Inc, H1 2020
Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Pipeline by Samsung Bioepis Co Ltd, H1 2020
Pipeline by Shandong Boan Biological Technology Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

【掲載企業】

Alteogen Inc
Benitec Biopharma Ltd
Cinnagen Co
Coherus BioSciences Inc
CSL Ltd
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Shandong Boan Biological Technology Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血管内皮増殖因子B治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆